The medication is also prescribed off-label for weight loss in individuals without diabetes
Cureus 15 , e46490 (2023)
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
Harvard and CDC study: Serious side effects from semaglutide are uncommon News briefs Reviewed by Anthony L
Weight loss from these medications also comes along with lifestyle changes, including a reduced-calorie diet and physical activity
This episode provides a modifiable foundational template that can be adjusted based on your current fitness level, goals, time constraints, and access to different types of equipment